Abstract 284
Background
In the United States, the incidence of developing colorectal cancer is < 5% in both males and females. The 5-year survival rates in stage IIA and IIB are 87% and 63% respectively. Surgery is the definitive treatment of stage II, while adding chemotherapy is still a debate. So we conducted this study to evaluate the efficacy of combined surgery and chemotherapy in the 5-year survival rates of stage II colorectal adenocarcinoma.
Methods
The data of 1231 patients with colorectal adenocarcinoma stage II from 2010 were collected using SEER database. There were 502 (41%) patients had combined chemotherapy and surgery, while 729 (59%) of them had surgery only. Patients’ demographics, carcinoembryonic antigen (CEA) test results, primary sites and sub stages of tumor were assessed.
Results
Patients with stage II colorectal adenocarcinoma who received combined surgery and chemotherapy had better 5-year relative survival rates (89%) than who went under surgery only (84.6%), (p-value <0.001). 5-year relative survival rates of combination were better in females (90.8%), negative CEA patients (93.4%), patients aged 20-40 years (100) and stage IIA (92.1%), (p-value <0.05). race and primary site of tumor were insignificant prognostic factors.
Table: 91P
| Variables | Survival of Patients | p value |
|---|---|---|
| CEA (carcinoembryonicantigen) positive Negative | 81.9% 93.4% | <0.05* |
| Sex Male Female | 87.3 % 90.8% | <0.05* |
| Age 20- 40 41- 60 61- 80 >80 | 100% 90.5% 87.9% 46.5% | <0.0001** |
| Race White Black Others | 89.2% 79.9% 92.6% | 0.261 |
Primary Site Ceacum Ascending colon Transverse colon Splenic flexure Descending colon Sigmoid colon Rectosigmoid junction Rectum | 74.5% 88% 91.9% 100% 89.8% 92.4% 86.8% 88.5% | 0.661 |
| Stage IIA IIB IIC | 92.1% 76.2% 63.4% | <0.0001** |
Highly significant P-value ≤ 0.001
*significant P-value <0.05
Conclusions
combined surgery and chemotherapy have better 5-year survival rates compared with surgery alone especially in those who are females, or have negative CEA test, aged 20-40 years or at stage IIA colorectal adenocarcinoma.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Faculty of Medicine Suez Canal University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.